News

Nycomed has submitted a marketing authorization application to the European Medicines Agency for Daxas as a once-daily oral treatment for patients with chronic obstructive pulmonary disease associated with

Gilead Sciences, a biopharmaceutical company, has reported encouraging data from DAR-311, a Phase III clinical trial evaluating the company’s once-daily oral endothelin receptor antagonist darusentan as an add-on

Helix BioMed, a developer of peptide molecules, has reported a net loss of $919,743 or $0.04 per share for the first quarter of 2009, compared to a net

Novavax, a clinical-stage biopharmaceutical company, has reported a net loss of $8.35m, or $0.12 per share, for the first quarter of 2009 compared to a net loss of

Denmark-based healthcare company Novo Nordisk has reported encouraging results from the Titrate study showing that Levemir, taken once-daily, substantially lowered average blood sugar. Approximately 60% of patients taking

PARI Pharma, a division of PARI GmbH and a developer of aerosol therapies, has received an orphan drug designation from the European Commission based on a positive recommendation

Implicit Bioscience, a biopharmaceutical company, and CMC Icos Biologics, a contract development and manufacturing organization, have signed a manufacturing contract to support the next stage of development and

Sanofi-aventis has reported the construction of a new Sanofi Pasteur vaccine manufacturing center in Neuville-sur-Saône, France. The investment in this new vaccine production facility, which is located close

Results Of Operations Three months ended March 31, 2009 as compared with three months ended March 31, 2008: Operating Revenues and Expenses For the three months ended March